Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Bactiguard Holding AB (publ)
  6. News
  7. Summary
    BACTI B   SE0005878741

BACTIGUARD HOLDING AB (PUBL)

(BACTI B)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Bactiguard : Aniocyn, now available in stores in the Nordic region

09/14/2021 | 03:41am EDT

Aniocyn, Bactiguard's wound care product for pets, is now available at Arken Zoo, Vetzoo and in Musti Group's other stores in Sweden, Norway and Finland. The product cleans and supports the natural wound healing by eliminating both bacteria, viruses and fungi, without irritating or stinging.

Musti Group reaches customers via the retail chains Musti and Mirri, Musti, Arken Zoo and Djurmagazinet as well as through the pure e-commerce channels Peten Koiratavirke and Vetzoo. Aniocyn is sold in more than 300 physical e-commerce stores in the region.

"We have an exciting autumn ahead of us together with Musti Group, the leading chain for pet products in the Nordic region. Being able to offer quality products for infection prevention and wound care for our pets, is something we are very much looking forward to", says Andreas Wallgren, General Manager Nordic at Bactiguard.

About Aniocyn
Aniocyn is a water-based solution for pets, intended to clean and support the natural healing of various types of wounds such as bites, lacerations, cuts and burns. Aniocyn reduces the risk of infection by eliminating bacteria, viruses and fungi without irritating the skin or stinging. The product contains no alcohol or preservatives and is safe in case of wound licking. Aniocyn can be used around sensitive areas such as eyes, mouth, nose and ears. It also reduces fetid wound odour.

For more information:
Andreas Wallgren, General Manager Nordic, mobile +46 70 637 97 49
 

About Bactiguard
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.

The Bactiguard technology is based on a thin noble metal alloy coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Urinary catheters with Bactiguard's coating are market leaders in the USA and Japan through our licensing partner BD. Bactiguard's product portfolio also includes a non-alcoholic product line for wound care and disinfection. It effectively kills viruses, bacteria and fungi while being biocompatible, pH neutral and tissue friendly. The active ingredient hypochlorous acid is the same substance as the body's immune cells use in their defence against infectious organisms.

Bactiguard is in a strong expansion phase in the markets in Europe, China, India and the Middle East through our own product portfolio and by establishing licensing deals in new therapy areas. Bactiguard has about 180 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia. Bactiguard is listed on Nasdaq Stockholm.

Read more about Bactiguard www.bactiguard.com

https://news.cision.com/bactiguard-holding-ab--publ-/r/aniocyn--now-available-in-stores-in-the-nordic-region,c3414367

https://mb.cision.com/Main/9686/3414367/1467901.pdf

https://news.cision.com/bactiguard-holding-ab--publ-/i/bactiguard-aniocyn,c2953685

(c) 2021 Cision. All rights reserved., source Press Releases - English

All news about BACTIGUARD HOLDING AB (PUBL)
10/08BACTIGUARD : More than 50% risk reduction of ventilator associated pneumonia with Bactigua..
PU
10/05BACTIGUARD : New clinical trial shows 53% reduction of ventilator-associated pneumonia wit..
PU
10/05BACTIGUARD : New clinical trial shows 53% reduction of ventilator-associated pneumonia wit..
AQ
10/05New Clinical Trial Shows 53% Reduction of Ventilator-Associated Pneumonia with Bactigua..
CI
09/30BACTIGUARD : Increased number of shares and votes in Bactiguard
AQ
09/27BACTIGUARD : Impact of COVID-19 on healthcare associated infections
PU
09/21BACTIGUARD : completes a directed new share issue to AMF, raising approximately SEK 228 mi..
AQ
09/21Bactiguard Holding AB announced that it has received SEK 228 million in funding from AM..
CI
09/14BACTIGUARD : Aniocyn, now available in stores in the Nordic region
AQ
09/11BACTIGUARD : Sepsis always starts with an infection – causes at least 11 M deaths gl..
PU
More news
Financials
Sales 2020 177 M 20,5 M 20,5 M
Net income 2020 -38,4 M -4,45 M -4,45 M
Net Debt 2020 254 M 29,5 M 29,5 M
P/E ratio 2020 -125x
Yield 2020 -
Capitalization 5 677 M 659 M 659 M
EV / Sales 2019 15,5x
EV / Sales 2020 28,6x
Nbr of Employees -
Free-Float 38,0%
Chart BACTIGUARD HOLDING AB (PUBL)
Duration : Period :
Bactiguard Holding AB (publ) Technical Analysis Chart | BACTI B | SE0005878741 | MarketScreener
Technical analysis trends BACTIGUARD HOLDING AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Managers and Directors
Anders Göransson Chief Executive Officer
Gabriella Björknert Caracciolo Chief Financial Officer & Deputy CEO
Nils Thomas von Koch Chairman
Stefan Grass Chief Medical Officer & Deputy CEO
Sathish Subramaniam Chief Operations Officer